Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q2 2019 · 10-Q
Revenue$4.94M$4.94M+14.2% vs Q2 2018 Net Income-$2.82M-$2.82MN/M vs Q2 2018 EPS Diluted-$3.93-$3.93no prior Q2 2018 on file Gross Profit$2,427,000+31.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,547,000N/M Free Cash Flowderived-$3,577,000N/M Margins · derivedGross margin49.1%+6.4 pt vs Q2 2018
Operating margin-53.7%+12.4 pt vs Q2 2018
Net margin-57.1%+9.3 pt vs Q2 2018
ended Sep 30, 2018 · filed Nov 8, 2018 · 39 d after period end